|
WO2021062039A2
|
|
T-cell compositions and methods of making and using the same
|
|
WO2021046411A1
|
|
System, method, and device for performing arthrography
|
|
WO2020257770A1
|
|
Methods and composition for a binding molecule targeting cancer cells expressing ssx2 peptide 41-49 in hla-a*0201 context
|
|
WO2020243729A1
|
|
Cytokine cocktails for selective expansion of t cell subsets
|
|
US2020349308A1
|
|
Predictive Modeling Platform for Serial Casting to Correct Orthopedic Deformities
|
|
WO2020146431A1
|
|
Improved targeted t-cell therapy for treatment of multiple myeloma
|
|
WO2020146434A2
|
|
Ex vivo activated t-lymphocytic compositions and methods of using the same
|
|
WO2020056383A1
|
|
Cells comprising antibodies against human immunodeficiency virus and methods of preparing and using the same
|
|
WO2021010951A1
|
|
Modified natural killer cells and methods of using the same
|
|
WO2020006454A1
|
|
Methods and system for dye-free visualization of blood flow and tissue perfusion in laparoscopy
|
|
WO2020006098A2
|
|
Tumor-associated markers for detection of minimal residual disease using digital droplet pcr
|
|
WO2019232548A2
|
|
Compositions and methods for treating and preventing muscular disorders and dystrophies, steroid side effects, and inflammation
|
|
WO2019222762A1
|
|
Improved cell therapy compositions for hematopoietic stem cell transplant patients
|
|
WO2019222760A1
|
|
Improved targeted t-cell therapy
|
|
AU2019260805A1
|
|
Mycobacterial antigen compositions and methods of use
|
|
WO2019204831A1
|
|
Fixed ratio ex vivo activated mixed lymphocyte products for use in the treatment of cancer
|
|
US2019282307A1
|
|
Dual-mode imaging system for tracking and control during medical procedures
|
|
KR20200122338A
|
|
Heptamethine cyanine for use as a fluorescent marker in the biliary tract and urinary system
|
|
EP3740115A1
|
|
A bioassay for the non-invasive detection of drug use and physiologic conditions
|
|
EP3720535A1
|
|
Soft cylindrical torque tool for medical devices with lumen
|
